# Brattea

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/brattea

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.brattea.com
- Total disclosed funding: $15M
- Latest round: Series D (Mar 25, 2024)
- Investors on record: 20

## About

Established in 2013 and based in Shanghai, China, Brattea is a medical equipment company that provides cardiology intervention therapy equipment. It has obtained 14 invention patents and 13 new utility patents, and has passed CE certification. The company's founder and CTO, Hongguang Cao served as a CTO of TCL Medical Group, and chairman of IRAY TECHNOLOGY COMPANY LIMITED. In March 2024, Brattea closed series D funding led by Zhongping Capital.

The company mainly provides Netrod ® mesh multi electrode renal artery radiofrequency ablation system (Netrod ® system) for high blood pressure. The Netrod ® system is an RDN (Renal Denervation) product, which supports the catheter inserted into the renal artery vessel and performed radiofrequency ablation on the sympathetic nerve of the renal artery. Brattea also provides EDN (Early Diabetic Nephropathy) treatment method, which can reduce glycosylated hemoglobin and be used to treat type II diabetes.

The company will use series D funding for the commercial promotion and clinical research of RDN products, clinical research of EDN products, as well as the research and development, registration application, and market development of other products.

## Funding rounds

- Series D, Mar 25, 2024 — Dingxin Capital, Shanghai Healthcare Capital, Hangzhou Xiaochi Private Equity Fund Management, Zhongping Capital
- Series C, Dec 22, 2022 — NNFE, Shanghai Fosun Pharmaceutical (Group), Hengxu Capital, Jianxing Medical Fund, Guangzhou Daxi Enterprise Management
- Series B, Apr 6, 2021, $15M — BrosMed Medical, Kuanping Capital, Hengxu Capital, Zhangjiang Torch Investment
- Series B, Jul 16, 2019 — BioTrack Capital, Sherpa Healthcare Partners
- Series B, Nov 24, 2016 — Bison Capital Asset Management, Marathon Venture Partners, Coastal Capital, Dalton Venture, Taizhou Jinlu Equity Investment Center
- Angel, Aug 15, 2013 — NLVC

## Investors

- NLVC (https://capitalatlas.ai/funds/nlvc) — Angel
- Bison Capital Asset Management (https://capitalatlas.ai/funds/bison-capital-asset-management) — Series B
- Marathon Venture Partners (https://capitalatlas.ai/funds/marathon-venture-partners) — Series B
- Coastal Capital (https://capitalatlas.ai/funds/coastal-capital) — Series B
- Dalton Venture (https://capitalatlas.ai/funds/dalton-venture) — Series B
- Taizhou Jinlu Equity Investment Center — Series B
- BioTrack Capital (https://capitalatlas.ai/funds/biotrack-capital) — Series B
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series B
- BrosMed Medical — Series B
- Kuanping Capital (https://capitalatlas.ai/funds/kuanping-capital) — Series B
- Hengxu Capital (https://capitalatlas.ai/funds/hengxu-capital) — Series B, Series C
- Zhangjiang Torch Investment (https://capitalatlas.ai/funds/zhangjiang-torch-investment) — Series B
- NNFE (https://capitalatlas.ai/funds/nnfe) — Series C
- Shanghai Fosun Pharmaceutical (Group) — Series C
- Jianxing Medical Fund — Series C
- Guangzhou Daxi Enterprise Management — Series C
- Dingxin Capital — Series D
- Shanghai Healthcare Capital (https://capitalatlas.ai/funds/shanghai-healthcare-capital) — Series D
- Hangzhou Xiaochi Private Equity Fund Management (https://capitalatlas.ai/funds/hangzhou-xiaochi-private-equity-fund-management) — Series D
- Zhongping Capital (https://capitalatlas.ai/funds/zhongping-capital) — Series D